1/130
Looks like no tags are added yet.
Disorders of Decreased Cell Count
RBCs: anemias
WBCs: leukopenia/neutropenia
Platelets: thrombocytopenia
Disorders of Increased/Abnormal Cell Proliferation
RBCs: polycythemia vera
WBCs: leukemia
Platelets: thrombocythemia
Anemia
Causes:
blood loss (GI, GU)
RBC destruction (hemolysis)
decreased RBC production
S/S:
fatigue
pallor
dizziness
shortness of breath
Classification:
Microcytic (small RBCs)
iron deficiency anemia (IDA)
thalassemia
Normocytic (normal RBC size)
aplastic anemia
hemolytic anemias (ex. sickle cell)
Macrocytic (large RBCs)
vitamin B12 deficiency
folate deficiency
Anemia Labs
CBC: complete blood count
RBC (million/μL)
Men: 4.5-5.5
Women: 4.0-5.0
Hemoglobin (Hgb) (g/dL)
Men: 14-18
Women: 12-16
Hematocrit (Hct) (%)
Men: 40-54
Women: 36-46
MCV: mean corpuscular volume
- RBC size (fL); normal 80-100 fL
microcytic: < 80 fL
normocytic: 80-100 fL
macrocytic: > 100 fL
MCH: mean corpuscular hemoglobin
- Hgb per RBC (pg); normal 27-33 pg
hypochromic: < 26 pg (pale)
normochromic: 26-33 pg
hyperchromic: > 33 pg (dark)
MCHC: mean corpuscular hemoglobin concentration
- Hgb concentration (g/dL); normal 32-36 g/dL
hypochromic: < 32 g/dL (decreased Hgb conc.)
normochromic: 32-36 g/dL
hyperchromic: > 36 g/dL (increased, rare)
RDW: red cell distribution width
- variation in RBC size (%); normal < 15%
> 15% = anisocytosis (increased variation in size)
Labs for Anemia
Iron Studies: iron deficiency anemia
serum iron (amount of iron in blood) —→ decreased
ferritin (iron stores) —> decreased
total iron-binding capacity (TIBC) (ability to bind iron) —> increased
Reticulocyte Count: shows bone marrow response
- Normal range: 0.5-1.5% of RBCs
Interpretation:
increased reticulocyte count:
blood loss
hemolysis (active bone marrow)
decreased reticulocyte count:
bone marrow suppression
decreased RBC production
Vitamin B12 & Folate Labs:
- both B12 and folate deficiencies cause macrocytic anemia
B12 deficiency:
decreased vitamin B12
increased methylmalonic acid (MMA)
increased homocysteine
Folate deficiency:
decreased folate
increased homocysteine (only)
Iron Deficiency Anemia (IDA)
- microcytic, hypochromic
Causes & Risk Factors:
inadequate iron intake, decreased absorption, or increased iron loss —> decreased iron available for Hgb synthesis —> decreased RBC production
- Common causes
chronic blood loss (ex. GI bleeding)
heavy menstrual bleeding (menstruation)
malabsorption (ex. celiac disease, gastric bypass)
increased demand (pregnancy, growth)
S/S:
fatigue, weakness, decreased exercise tolerance
pallor (mucous membranes, conjunctiva, nail beds)
dyspnea (with exertion)
headache
brittle nails (koilonychia)
hair loss
glossitis (smooth, red tongue)
pica (ex. ice, nonfood items)
Diagnostic Findings:
- CBC:
decreased Hgb/Hct
decreased MCV
decreased MCH
increased RDW (increased variation in RBC size)
- Peripheral smear:
microcytic, hypochromic RBCs with anisocytosis and poikilocytosis (pencil cells may be seen)
- Iron studies:
decreased serum iron
dcreased ferritin (low iron stores)
increased TIBC
- Other:
reticulocyte usually normal or low (decreased production)
Treatment:
- Oral iron supplements (first-line)
Ex, ferrous sulfate, ferrous gluconate, ferrous fumarate
take with vitamin C to enhance absorption
common side effects: GI upset, constipation, dark stools
- IV iron therapy —> use if unable to tolerate oral iron, malabsorption, or need for rapid repletion (ex. severe deficiency, pregnancy, chronic kidney disease)
- Treat underlying cause:
address source of blood loss
manage conditions causing malabsorption
provide dietary eduction
Ferrous sulfate
Class: iron supplement
Use: treats iron deficiency anemia (IDA)
MOA: replaces iron —> supports hemoglobin synthesis and RBC production
Dose: adult PO: 325 mg (about 65 mg elemental iron), 1-3x day
ADR: constipation, dark stools, dyspepsia, rash; liquid may stain teeth; anaphylaxis more with IV administration
Interactions: antacids, PPIs, calcium, tetracyclines —> decreased iron absorption
Contraindications/Cautions: hemochromatosis; uses caution with PUD or UC
Nursing: monitor Hgb/Hct and response; give with vitamin C to increase absorption
Key point: separate from calcium/antacids and interacting medications; consider stool softener PRN
Vitamin B12 Deficiency Anemia
Cause:
decreased intake (vegan diet)
decreased absorption (gastric surgery, malabsorption)
Key Effects:
decreased DNA synthesis —> macrocytic anemia
neurologic involvement (paresthesia, imbalance, memory changes)
Clinical Features:
fatigue, pallor
macrocytic anemia
neurologic symptoms: paresthesia, imbalance, memory changes
Diagnostic Findings:
increased MCV
macro-ovalocytes
hypersegmented neutrophils
decreased B12
increased methylmanoic acid (MMA)
Treatment: cyanocobalamin (oral or IM)
Pernicious Anemia
Cause:
autoimmune loss of intrinsic factor
impaired B12 absorption
Key Effects:
decreased DNA synthesis —> macrocytic anemia
neurologic involvement (same as B12 deficiency)
lifelong replacement needed
Clinical Features:
fatigue, pallor
macrocytic anemia
neurologic symptoms: paresthesia, imbalance, memory changes
Diagnostic Findings:
increased MCV
macro-ovalocytes
hypersegmented neutrophils
positive intrinsic factor antibodies
decreased B12
increased methylmalonic acid (MMA)
Treatment: lifelong B12 replacement (oral or IM)
Folate (B9) Deficiency
Cause:
decreased intake (poor diet, alcoholism)
increased demand (pregnancy)
Key Effects:
decreased DNA synthesis —> macrocytic anemia
no neurologic symptoms
increased risk of fetal neural tube defects
Clinical Features:
fatigue, pallor
macrocytic anemia
no neurologic symptoms
increased risk of fetal neural tube defects (pregnancy)
Diagnostic Findings:
increased MCV
macro-ovslocytes
hypersegmented neutrophils
decreased folate
methylmalonic acid (MMA) usually normal
Treatment: oral folic acid; correct underlying cause
Cyanocobalamin (Vitamin B12)
Class: vitamin supplement
Use: treats B12 deficiency and pernicious anemia
MOA: replaces B12 —> restores DNA synthesis and RBC production, division, and maturation
ADR: headache, nausea, diarrhea, possible hypokalemia during rapid correction
Interactions: omeprazole may decrease B12 absorption; chloramphenicol may decrease hematologic response
Nursing: assess CBC, reticulocytes and neurologic symptoms; oral or IM based on need
Daily Requirement: adults —> 2.4 mcg, pregnancy 2.6 mcg, lactation 2.8 mcg
Key point: pernicious anemia requires lifelong B12 replacement; monitor neurologic recovery
Folic acid (Vitamin B9)
Class: water-soluble vitamin
Use: treats folate-deficiency anemia
MOA: supports DNA synthesis —> normal RBC production
ADR: generally well tolerated; warmth or flushing with IV administration
Interactions: methotrexate and phenytoin can affect folate levels or treatment
Nursing: give before contraception and during pregnancy; assess cause of deficiency
Daily requirement: adults —> 400 mcg, pregnancy —> 600 mcg, lactation —> 500 mcg
Key point: folate helps prevent neural tube defects; exclude B12 deficiency before folate-only treatment
Anemia of Chronic Disease (AOCD)
Mechanism: chronic inflammation leads to decreased RBC production, decreased iron availability, and shortened RBC lifespan
- Chronic inflammation —> cytokines (ex. IL-6, TNF-alpha)
increased hepcidin
directly suppresses erythropoietin (EPO) production
- Decreased iron availability
increased hepcidin reduces intestinal iron absorption and traps iron in macrophages
- Decreased erythropoietin (EPO) response
inflammatory cytokines suppress renal erythropoietin (EPO) production
- Decreased RBC production
inadequate bone marrow response
- Decreased RBC lifespan
RBC lifespan shortened from 100-120 days to 60-90 days
Causes:
chronic infection (HIV, TB)
chronic immune activation (RA, SLE)
malignancy (Hodgkin’s lymphoma, lung cancer, breast cancer)
chronic kidney disease (CKD) —> decreased erythropoietin production —> decreased RBC production
Treatment:
Control underlying disease/inflammation
treat infections (HIV, TB)
manage autoimmune disease (RA, SLE)
treat malignancy
optimize CKD management
Erythropoietin (EPO) therapy if CKD-related
consider erythropoietin (EPO) therapy in CKD-related anemia
Leukopenia & Neutropenia
Definitions:
Leukopenia
WBC < 4,000 μL
decrease in total white blood cells
Neutropenia
neutrophils < 1,500 μL (severe < 500 μL)
high risk for infection
Normal vs Neutropenia:
Normal: 1,500-8,000 μL (adequate infection defense)
Neutropenia: < 1,500 μL (fewer neutrophils —> increased infection risk)
severe: < 500 μL
Causes:
chemotherapy and radiation
bone marrow disorders or suppression
infections (viral, bacterial)
medications (ex. antineoplastics)
autoimmune disorders
nutritional deficiency (ex. vitamin deficiency)
chronic illness
S/S:
often asymptomatic
fatigue
fever and chills
recurrent infections
mouth ulcers
pneumonia
increased risk for serious infection
Diagnostics:
CBC with differential (decreased WBC and ANC)
blood cultures (if fever)
bone marrow biopsy (if indicated)
Treatment:
G-CSF (Filgrastim) —> increased WBC production
antibiotics —> prevent or treat infection
adjust causative medications
bone marrow transplant (if severe or refractory)
Neutropenic Fever: MEDICAL EMERGENCY
fever ≥ 100.4 °F in a neutropenic patient
report immediately
obtain blood cultures (as ordered)
start empiric broad-spectrum antibiotics (as ordered)
monitor vital signs and CBC (WBC, ANC)
Filgrastim (Neupogen)
Class: hematopoietic growth factor; granulocyte colony-stimulating grwoth factor (G-CSF)
MOA: stimulates bone marrow —> increased neutrophil production (ANC)
Uses: chemo-induced neutropenia; after stem cell transplant; selected severe neutropenias
ADR: bone pain; leukocytosis; rare but splenic rupture or ARDS
Contraindications: serious hypersensitivity
Interactions: avoid administration within 24 hours before or after cytotoxic chemotherapy
Similar Drugs: pegfligrastin (Neulasta) —> longer acting
Nursing: monitor CBC/ANC; follow prescribed hold parameters; assess bone pain
Safety: report fever, left upper abdominal/shoulder pain, or breathing difficulty promptly
Key point: ANC-based dose adjustments depend on indication and protocol — not one universal cutoff
Thrombocytopenia
Definition & Platelet Levels:
platelets < 150,000 μL
increased bleeding risk when < 50,000 μL
severe spontaneous bleeding when < 20,000 μL
Causes:
- decreased production (bone marrow failure)
aplastic anemia
leukemia
chemotherapy
radiation
- increased destruction
immune thrombocytopenic purpura (ITP) — autoimmune
infections (ex. HIV, HCV)
drugs (ex. heparin induced thrombocytopenia — HIT)
- increased consumption
disseminated intravascular coagulation (DIC)
thrombotic thrombocytopenic purpura (TTP)
S/S:
purpura
petechiae
prolonged bleeding
epistaxis
bleeding gums
hematuria
melena
Diagnostics:
CBC —> decreased platelets
peripheral smear
± bone marrow biopsy (if indicated)
Management:
mild thrombocytopenia —> treat underlying cause
ITP: steroids/IVIG/ ± splenectomy/TPO agonists
marrow suppression (chemo): thrombopoietic CSF (romiplostim, oprelvekin)
severe ( < 10,000 or active bleeding): platelet transfusion
Nursing:
monitor platelet count and assess for bleeding
implement bleeding precautions
soft toothbrush
electric razor
avoid NSAIDs, IM injections, and invasive procedures
report any bleeding or bruising
Leukemia
Definition:
acute or chronic, uncontrolled proliferation of abnormal WBCs in bone marrow and blood
malignant disorder of hematopoietic (blood-forming) cells
M = myeloid —> granulocytes, RBC, platelets
L = lymphocytic —> lymphocytes (B & T cells)
Types:
Acute (AML, ALL):
rapid increase of immature blasts
medical emergency
Chronic (CML, CLL):
slow increase of more mature but dysfunctional WBCs
often asymptomatic early
Causes/Risk Factors:
genetic: Philadelphia chromosome (especially CML)
environmental: radiation, chemical exposure (ex. benzene)
Clinical Manifestations:
fatigue
fever
weight loss
increased infections (due to dysfunctional WBCs)
easy bruising/bleeding (decreased platelets)
bone pain
lymphadenopathy (enlarged lymph nodes)
Diagnostics:
increased WBC count on CBC (often with abnormal/dysfunctional cells)
peripheral smear (abnormal cells, blasts)
bone marrow biopsy (increased blasts)
genetic testing (ex Philadelphia chromosome in CML)
Treatment:
chemotherapy: decreased blasts
targeted therapy (TKIs): inhibits specific genetic abnormalities
stem-cell transplant: curative option for selected patients
supportive care: transfusions, infection prevention
Key point:
- Leukocytosis
reactive/adaptive increase in WBCs (ex. infection, inflammation, stress, certain medications)
WBCs usually mature and functional
- Leukemia
malignant proliferation of abnormal WBCs
WBCs often immature and dysfunctional (blasts)
Polycythemia Vera (PV)
Defintion:
chronic myeloproliferative neoplasm with a JAK2 mutation leading to persistent increase in RBC production
often associated with increased WBCs and platelets
Types of Erythrocytes:
- Primary
myeloproliferative neoplasm
JAK2 mutation (about 95%)
clonal overproduction of RBCs (often increase in WBCs and platelets)
low erythropoietin (EPO)
- Secondary
due to increased EPO from chronic hypoxia or other cuases (ex. lung/heart disease, high altitude, smoking, tumors)
JAK2 mutation absent
normal or increased EPO
Patho:
JAK2 mutation (constitutive activation)
uncontrolled RBC production (± increased WBCs and platelets)
increased blood viscosity
increased risk for thrombosis (arterial and venous)
Diagnostics:
CBC —> increased RBC count, Hgb, Hct (± WBCs/platelets)
JAK2 mutation testing
low serum erythropoietin (EPO)
bone marrow biopsy (hypercellular marrow with panmyelosis, if indicated)
S/S:
headache
dizziness
ruddy complexion (plethora)
aquagenic pruritus (itching after warm shower)
fatigue
erythromelalgia (burning, redness in hands/feet)
increased risk for thrombosis (DVT, PE, MI, stroke) or bleeding (especially with very high platelets)
Treatment:
Phlebotomy
first-line treatment
goal: hematocrit < 45%
low-dose aspirin (81-100 mg/day)
decreased thrombotic risk (if no contraindications)
hydroxyurea
cytoreductive therapy
decreased RBC, WBC, and platelet production
ropeginterferon alfa-2b (Besremi)
pegylated interferon (JAK2 pathway)
decreased JAK2-mutant stem cell activity
Key point:
- PV
JAK2 mutation (positive)
primary bone marrow disorder
increased RBC mass (± WBCs and platelets)
low EPO
- Secondary (reactive) Eryhthrocytosis
no JAK2 mutation
due to increased EPO (ex. chronic hypoxia, lung/heart disease, high altitude, smoking, tumors)
Essential Thrombocythemia (ET)
Defintion:
chronic myeloproliferative neoplasm with a JAK2 mutation leading to increased persistent platelet production
clonal overproduction of megakaryocytes in bone marrow
Types:
- Primary
myeloproliferative neoplasm
JAK2 mutation (50-60%)
clonal overproduction of megakaryocytes (increased platelets)
- Secondary
response to another condition (ex. inflammation, infection, iron deficiency, malignancy, or post-splenectomy)
JAK2 mutation absent
normal or increased other labs related to cause
Patho:
JAK2 mutation (constitutive activation)
increased megakaryocyte production in bone marrow
increased platelets
increased risk for thrombosis (arterial and venous) ± bleeding
Diagnostics:
CBC: increased platelets (> 450,00)/μL)
JAK2 mutation testing (for ET)
bone marrow biopsy (increased megakaryocytes, if indicated)
Clinical Manifestations:
often asymptomatic
headache, dizziness, visual changes
increased thrombosis risk (ex. stroke, MI, DVT)
± easy bruising/bleeding (ex. gums, nose)
erythromelalgia (burning, redness in hands/feet)
Treatment:
antiplatelet agent (low-dose aspirin) —> decreased clot risk. (if no contraindications)
cytoreductive therapy (hydroxyurea or anagrelide) —> decreased platelet production
monitor for thrombosis and bleeding
Key point:
- ET:
primary bone marrow disorder (JAK2 mutation)
persistent increased platelets ( > 450,000 μL)
treat with aspirin ± hydroxyurea or anagrelide
- Reactive (secondary) Thrombocytosis
due to another condition (infection, inflammation, iron deficiency, malignancy, post-splenectomy)
JAK2 mutation absent
usually transient and treat underlying cause
Aplastic Anemia
Definition: bone marrow failure —> decreased production of all blood cells (pancytopenia) —> anemia + leukopenia + thrombocytopenia
Causes:
autoimmune destruction
radiation
toxins (ex. benzene)
drugs (ex. chloraphenicol)
S/S:
fatigue (decreased RBCs)
infections (decreased WBCs)
bleeding (decreased platelets)
Findings:
decreased RBCs, WBCs, platelets (pancytopenia)
normocytic, normochromic RBCs
decreased reticulocytes
bone marrow failure: hypocellular marrow replaced by fat (hallmark)
normal iron, B12, folate levels
Treatment:
bone marrow stimulants
epoetin alfa, filgrastin
immunosuppressive therapy
antithymocyte globulin (ATG) + cyclosporine
immune destruction —> marrow recovery
bone marrow transplant
iff severe or refractory
Epoetin Alfa (Epogen)
Class: hematopoietic growth factor; erythropoietin
MOA: stimulates RBC production in bone marrow
Use: anemia due to CKD, chemotherapy, or HIV therapy
ADR: fever, headache, N/V/D, edema; hypertension
Black Box: increased risk of clots, stroke, MI, and death
Contraindications: uncontrolled HTN; avoid excessive Hgb rise
Interactions: dialysis patients may need more hepain
Similar drugs: darbepoetin alfa (Aranesp)
Nursing:
monitor BP, Hgb/Hct; assess for DVT, stroke, MI
DO NOT shake vial; use the lowest effective dose
Myelodysplatic Syndromes (MDS)
Overview: group of bone marrow disorders where stem cells fail to mature properly —> produce abnormal, ineffective blood cells
Patho:
defective maturation (dysplasia) of hematopoietic stem cells in the bone marrow
leads to production of abnormal, ineffective blood cells and increased apoptosis —> cytopenias
Result: decreased production of healthy RBCs, WBCs, and platelets —> pancytopenia
Clinical Manifestations:
anemia —> fatigue, pallor, dyspnea
neutropenia —> increased infection risk
thrombocytopenia —> bleeding, petechiae
often gradual onset and may be asymptomatic
Progression: damaged marrow may evolve to acute myeloid leukemia (AML)
Management:
Supportive care
transfusions
antibiotics
Stimulants
EPO
G-CSF
Drug therapy (chemotherapy)
azacitidine
decitabine
Curative option
bone marrow transplant
Thalassemia
Definition: genetic disorder
doesn’t make enough normal Hgb chains (alpha or beta) so the RBCs are fragile and break down early —> microcytic anemia
autosomal recessive inheritance (both parents must be carriers)
Types:
- Alpha
1-4 gene deletions —> severity ranges from mild to fatal
more common in Southeast Asian, Chinese, and African ancestry
- Beta
decreased Beta-chain production —> trait minor, intermedia, or major
more common in Mediterranean, Middle Eastern, and Asian ancestry
Patho:
abnormal and/or not enough alpha or beta globin chains
imbalanced globin chains (excess unpaired chains)
ineffective erythropoiesis and increased RBC destruction (hemolysis)
microcytic and hypochromic anemia because not enough Hgb
S/S:
fatigue
pallor (conjuctiv, mucous membranes)
splenomegaly
dark urine (hemoglobinuria in severe hemolysis)
Diagnostic Findings:
- CBC:
decreased Hgb/Hct
decreased MCV (microcytic)
decreased MCH (hypochromic)
- Peripheral smear:
microcytic, hypochromic RBCs with target cells
- Iron studies:
usually normal (unlike iron deficiency anemia)
- Hemoglobin electrophoresis:
confirms diagnosis (especially Beta-thalassemia)
Treatment:
Blood transfusions
for moderate to severe anemia
corrects anemia and improves symptoms
Iron chelation therapy
prevents iron overload from repeated transfusions
ex. deferoxamine, deferasirox, deferiprone
Supportive care
folic acid, monitor for complications (ex. growth, bone changes)
Key point: abnormal and/or not enough alpha or beta globin changes —> fragile RBCs that break down early; microcytic and hypochromic anemia because not enough Hgb, not iron deficiency
Hemolytic Anemia
Definition: premature destruction of RBCs —> anemia
Causes:
autoimmune (ex. warm or cold antibodies)
hereditary (ex. G6PD deficiency, hereditary spherocytosis, thalassemia)
infections (ex. malaria)
drugs (ex. sulfa, dapsone)
G6PD deficiency (cause): decreased G6PD enzyme —> oxidative stress —> RBC destruction (especially with certain drugs, food, or infections)
Patho:
RBC membrane damage or enzyme deficiency
RBCs destroyed in circulation or spleen
increased bilirubin, LDH, and decreased haptoglobin
Diagnostics:
- CBC:
decreased Hgb, Hct (anemia), increased reticulocytes (if bone marrow is responding)
increased bilirubin (indirect), increased LDH
decreased haptoglobin
peripheral smear (ex. spherocytes, fragmented cells, target cells —> depending on cause)
S/S:
fatigue, weakness
jaundice (yellowing of skin/eyes)
dark urine
splenomegaly (especially with chronic hemolysis)
possible pain (ex. in malaria)
Treatment:
treat underlying cause (ex. remove trigger, treat infection)
folic acid supplementation (increased RBC production)
blood transfusions (if severe anemia)
corticosteroids or immunosuppressants (for autoimmune hemolysis)
avoid triggering drugs/foods (G6PD deficiency)
avoid oxidizing drugs (ex. sulfa, dapsone, antimalarials), flava beans, and infections
supportive care (ex. hydration, treat precipitating factors)
Sickle Cell Anemia
Definition & Patho:
genetic disorder —> abnormal hemoglobin (HbS)
sickle-shaped, rigid RBCs —> vaso-occlusion (obstructs blood flow and decreased O2 delivery to tissues)
inherited in an autosomal recessive pattern —> both parents must carry the gene
Diagnostics:
sickle-shaped RBCs on peripheral smear
hemoglobin electrophoersis —> shows HbS
decreased Hgb/Hct, increased reticulocytes (chronic hemolysis)
increased bilirubin (jaundice)
may see pigment gallstones on imaging
S/S:
pain crisis —> vaso-occlusion & tissue ischemia
fatigue —> anemia & decreased O2 delivery
jaundice —> increased RBC breakdown
delayed growth —> chronic hypoxia
organ damage —> spleen, kidneys, liver, heart
Complications:
acute chest syndrome —> pneumonia, lung infarcts
stroke —> blocked cerebral vessels
organ damage —> spleen, liver, kidneys (infarcts —> chronic kidney disease)
retinal infarcts —> blindness
avascular necrosis —> femoral ehad
iron overload —> heart, liver (due to repeated transfusions)
increased risk for infections —> asplenia (functional)
osteomyelitis —> bone infarction (fingers and toes)
Treatment & Crisis Care:
- Disease modifying treatment
hydroxyurea —> fetal hemoglobin (HbF) —> decreased sickling
blood transfusions —> prevent/treat selected complications
hematopoietic stem cell transplant —> potentially curative (selected patients)
avoid unnecessary iron supplementation —> give only if iron deficient
- Acute pain crisis (vaso-occlusion)
rapid pain management —> opioids for severe pain
hydration —> maintain euvolemia (avoid fluid overload)
O2 therapy —> hypoxemic
incentive spirometry —> prevent pulmonary complications
monitor —> SpO2, pain, fever, respiratory status
- Acute chest syndrome (EMERGENCY)
oxygen —> correct hypoxemia
antibiotics —> empiric coverage (including atypicals)
incentive spirometry
analgesia
blood transfusion (when indicated)
exchange transfusion —> severe or rapidly worsening cases
Hydroxyurea
Class: antineoplastic agent; antimetabolite
Use: sickle cell anemia; polcythemia vera; essential thrombocythemia, chronic myeloid leukemia (CML)
MOA: increased fetal hemoglobin (HbF) —> decreased sickling and pain crises AND inhibits enzyme that makes DNA —> decreased DNA synthesis and production of blood cells (RBC, WBC, platelets)
ADR: bone marrow suppression (decreased WBCs, platelets); N/V
Nursing: monitor CBC; hold for low counts per protocol; report fever/infetion
Safety: use gloves to handle capsules; avoid pregnancy
Teaching: take as prescribed; maintain hydration; keep lab appointments
Key point: prevents crises — it does not treat an acute crisis
Hemostasis
Definition: how the body stops bleeding
Steps:
Vasoconstriction —> injured vessel narrows to reduce blood loss
Platelet plug (primary hemostasis) —> platelets stick to the injury and build a temporary plug
Coagulation (secondary hemostasis) —> a clotting fator cascade generates fibrin to strengthen and stabilize the plug
Coagulation:
Initiation (extrinsic pathway): injury exposes tissue factor (TF), which quickly starts the cascade
Amplification (intrinsic pathway): activates additional factors to make more Factor X and thrombin (strengthens the response)
Common pathway: Factor Xa + Factor Va convert prothrombin (Factor II) to thrombin (Factor IIa), which converts fibrinogen to fibrin
Clot stabilization: Factor XIIIa cross-links fibrin strands to make a strong, stable clot
Key points:
extrinsic pathway initiaties coagulation
intrinsic pathway amplifies the response
thrombin drives positive feedback
Factor XIIIa stabilizes the clot by cross-linking fibrin
Coagulation Disorders & Modifiers
Hypercoagulability:
increased clot formation
excessive coagulation or impaired natural anticoagulation
Ex.
Factor V Leiden
Antiphospholipid syndrome
DVT/PE
Bleeding disorders:
decreased effective clot formation
platelet abnormalities, clotting-factor deficiencies, or excessive fibrinolysis
Ex.
hemophilia
Von Willebrand disease
ITP
DIC
Coagulation modifiers:
medications alter clot formation or breakdown
may inhibit clotting, dissolve exisiting clots, or promote hemostasis
Ex.
antiplatelets
anticoagulants
thrombolytics
hemostatic agents
Coagulation & Hemostasis Tests
Coagulation pathways:
PT/INR —> extrinsic/common pathways; monitors warfarin
aPTT —> intrinsic/common pathways; monitors IV heparin
anti-Xa —> monitors selected heparin therapy
Platelets/Primary hemostasis:
platelet count —> identifies thrombocytopenia and bleeding risk
Other:
D-dimer —> fibrin breakdown; negative result helps rule out DVT/PE in low-risk patients
liver function tests —> liver produces most clotting factors
Key point: elevated D-dimer is non specific; it does NOT confirm DVT/PE
Inherited (Genetic) Hyper-coagulable Disorders
Factor V Leiden:
mutation in factor V —> resistance to activated Protein C (decreased inactivation of factor V)
increased risk for DVT/PE
Prothrombin gene mutation (G20210A):
increased prothrombin production
increased clot formation
Protein C/S deficiency:
decreased natural anticoagulation (less inhibition of clotting)
increased thrombosis risk
Antithrombin deficiency:
decreased inhibition of thrombin and Factor Xa
increased thrombosis risk
Acquired Hypercoagulable Disorders & Risk Factors
Antiphospholipid Syndrome (APS):
autoantibodies (lupus anticoagulant, anticardiolipin) that promote clot formation
venous/arterial thrombosis and recurrent pregnancy loss
Malignancy: increased procoagulant activity from cancer cells
Pregnancy, Postpartum, and Estrogen Exposure: increased clotting factors
Immobility: venous stasis (slower blood flow)
Surgery/Trauma: tissue injury + immobility —> increased clotting risk
Hyper-coagulability Clinical Manifestations & Managment
Patho:
hyper-coagulability —> increased thrombin —> increased fibrin —> increased pathologic clot formation
vascular obstruction —> decreased perfusion —> ischemia or infarction
Clinical manifestations:
DVT —> unilateral leg swelling, pain, warmth, redness
PE —> sudden dyspnea, chest pain, tachycardia
Other complications —> stroke, MI, tissue ischemia
Management & prevention:
anticoagulants —> heparin, LMWH, warfarin, DOACs
prevention —> early ambulation, sequential compression devices (SCDs), hydration, smoking cessation
nursing priorities —> monitor for thrombosis, bleeding, and treatment complications
Antithrombotic Therapy
Purpose: prevent or treat harmful blood clot formation (DVT, PE, stroke, ACS)
Mechanism: reduce platelet aggregation, inhibit clotting factors, or dissolve fibrin clots
Major drug classes & examples:
Antiplatelets —> aspirin (decreased TXA2); clopidogrel (blocks P2Y12); eptifibatide (GP IIb/IIIa)
Anticoagulants —> heparin/LMWH (increase antithrombin); warfarin (decrease vitamin K factors); DOACs (inhibit IIa or Xa)
Thrombolytics —> alteplase, tenectap;ase (activate plasmin to break down fibrin
Major risk: bleeding, including intracranial hemorrhage with thrombolytics
Key point:
anticoagulants prevent clot growth
thrombolytics dissolve existing clots
Aspirin (Acetylsalicylic Acid)
Class: antiplatelet; COX-1 inhibitor
MOA: irreversibly inhibits COX-1 —> decreased Thromboxane A2 —> decreased platelets activation and aggregation
Route: PO
Major ADR: bleeding, GI irritation/ulcers
Safety: avoid with active bleeding; Reye’s syndrome risk in children with viral illness
Clopidogrel (Plavix)
Class: antiplatelets; P2Y12 (ADP) receptor inhibitor
Similar Drugs: prasugrel (Effient), ticagrelor (Brilinta)
MOA: blocks P2Y12 receptors —> decreased platelet activation and aggregation
Route: PO
Major ADR: bleeding/hemorrhage
Black Box: reduced effectiveness in CYP2C19 poor metabolizers
Nursing:
monitor: bleeding, bruising, black/tarry stools
interactions: NSAIDs/anticoagulants —> increased bleeding risk
teaching: do not stop prescribed therapy without provider instructions
Key point: antiplatelets prevent platelet aggregation —> help prevent arterial clots
Eptifibatide
Class: antiplatelet; GP IIb/IIIa inhibitor
MOA: blocks GP IIb/IIIa receptors —> prevents fibrinogen binding —> decreased platelet aggregation
Route: IV
Use: ACS and other selected coronary interventions
Major ADRs: severe bleeding, thrombocytopenia
Nursing:
monitor: bleeding, platelet count, hemoglobin/hematocrit
assess: IV/access sites —> bleeding or hematoma
renal function: decreased kidney function —> may require dose adjustment
interactions: anticoagulants/other antiplatelets —> increased bleeding risk
safety: avoid unnecessary invasive procedures; report significant bleeding
Key point: GP IIb/IIIa inhibitors block the final common step of platelet aggregation
Heparin
Class: anticoagulant
MOA: inhibits Factor Xa and thrombin (IIa)
Route: IV or SC —> rapid anticoagulation
Major ADR: bleeding, heparin-induced thrombocytopenia (HIT)
Monitoring: aPTT or anti-Xa, platelets
Antidote: protamine sulfate
Key point: monitor bleeding, avoid IM injections
aPTT/anti-Xa monitoring
Low-molecular weight heparin (LMWH)
Class: anticoagulant
Prototype: Enoxaparin
MOA: mainly inhibits Factor Xa
Route: SC —> rotate injection sites; do not rub
Major ADR: bleeding; HIT less common
Monitoring: no routine aPTT; monitor platelets and renal function
Reversal: protamine sulfate —> partial reversal
Nursing:
monitor bleeding; avoid IM injections
Black Box: spinal/epidural bleeding —> possible paralysis
Key point: no routine aPTT monitoring
Heparin-induced Thrombocytopenia (HIT)
Definition: serious immune reaction to heparin —> increased platelet activation —> increased blood clots (thrombosis)
Patho: antibodies form against heparin-PF4 complexes —> platelets become activated and consumed —> decreased platelet count
Key finding: ≥ 50% drop in platelets from baseline —> usually occurs 5-10 days after starting heparin
S/S: new DVT/PE, limb pain/ischemia or skin necrosis —> indicates possible thrombosis
Nursing:
monitor: platelet trends —> ≥ 50% decrease or new thrombosis —> suspect HIT
take action: suspected HIT —> STOP all heparin (including flushes) —> notify provider immediately
treatment: stop heparin —> and astart alternative non-heparin anticoagulant (ex. argatroban, bivaliriudin — IV direct thrombin inhibitors)
safety: avoid LMWH and routine platelet transfusions in acute HIT
Key point: HIT = decreased platelets but increased risk of blood clots — NOT primary bleeding
Warfarin (Coumadin)
Class: anticoagulant; vitamin K antagonist
MOA: blocks vitamin K recylcing —> decreased production of clotting factors II, VII, IX, X
Route: PO —> delayed anticoagulant effect
Major ADR: bleeding/hemorrhage
Black Box: major or fatal bleeding
Contraindications: active major bleeding; generally avoided in pregnancy
Interactions: many medications and changes in vitamin K intake affect INR
Nursing:
monitor: PT/INR —> usually 2-3; some mechanical valves require higher targets
diet: maintain consistent vitamin K intake (leafy greens)
antidote: vitamin K (phytonadione)
severe bleeding: 4-factor prothrombin complex concentrate (PCC) + IV vitamin K
teaching: regular INR checks; report bleeding
Key point:
INR monitoring + vitamin K reversal
used for mechanical heart valves; DOACs are not
Apixaban (Eliquis)
Class: direct oral anticoagulant (DOAC)
MOA: blocks factor Xa —> decreased thrombin formation
Route: PO —> usually twice daily
Major ADR: bleeding/hemorrhage
Reversal: 4-factor PCC may be used for severe bleeding per protocol
Nursing:
monitoring: no routine INR or aPTT; assess bleeding, CBC, kidney function
interactions: NSAIDs/aspirin —> increased bleeding risk
black box: stopping early —> increased thrombosis; spinal/epidural bleeding risk
teaching: do NOT stop abruptly; take consistently
Dabigatran (Pradaxa)
Class: direct oral anticoagulant (DOAC)
MOA: blocks thrombin (IIa) —> decreased fibrin formation
Route: PO —> usually twice daily
Major ADR: bleeding/hemorrhage
Reversal: idarucizumab (Praxbind) —> specific antidote)
Nursing:
monitoring: no routine INR or aPTT; assess bleeding, CBC, kidney function
interactions: NSAIDs/aspirin —> increased bleeding risk
black box: stopping early —> increased thrombosis; spinal/epidural bleeding risk
teaching: do NOT stop abruptly; take consistently
Nursing considerations anticoagulants
Assess for bleeding: bruising, bleeding gums, hematuria, black/tarry stools
Monitor for thrombosis: leg swelling/pain, sudden dyspnea, chest pain
Avoid NSAIDs/aspirin unless prescribed: increased bleeding risk
Bleeding precautions: soft toothbrush, electric razor, prevent falls/injury
Before procedures: notify provider; anticoagulants may need to be held as ordered
Patient education: take exactly as prescribed; never skip, double, or stop doses without instructions
Report immediately: uncontrolled bleeding or symptoms of DVT/PE
Key point: anticoagulants prevent clot formation but increase bleeding risk
Alteplase (Activase)
Class: thrombolytics (fibrinolytics)
Similar drugs: tenecteplase (TNKase)
MOA: converts plasminogen —> plasmin —> breaks down fibrin —> dissolves existing clots
Route: IV; may be delivered delivered to a clot during selected procedures
Use: select patients with acute ischemic stroke, PE, or MI
Major ADR: severe bleeding, especially intracranial hemorrhage
Contraindications: active bleeding, intracranial hemorrhage, or other major bleeding risks
Nursing:
before administration: screen for contraindications; verify treatment eligibility and timing
monitor: neurological status, vital signs, bleeding
safety: avoid unnecessary injections/invasive procedures
report immediately: severe headache, sudden neurological changes, or bleeding
Key point: anticoagulants prevent clot growth; thrombolytics dissolve existing clots
Bleeding Disorders
Platelet adhesion disorders:
Von Willebrand Disease (VWD) —> inherited deficiency or dysfunction of von Willebrand factor; impaired platelet adhesion
Clotting factor deficiencies:
hemophilia A —> Factor VIII deficiency
hemophilia B —> Factor IX deficiency
Platelet destruction disorders:
immune thrombocytopenia (ITP) —> acquired autoimmune destruction of platelets
Consumptive coagulopathies:
disseminated intravascular coagulation (DIC) —> widespread clotting consumes platelets and clotting factors, results in bleeding
Von Willebrand Disease (VWD)
Defintion: most common inherited bleeding disorder —> deficiency or dysfunction of vWF (platelet adhesion defect)
- vWF Types:
Type 1: decreased vWF quantity (mild, most common)
Type 2: decreased vWF function
Type 3: nearly absent vWF (severe, rare)
Testing: decreased vWF antigen/activity, ± decreased Factor VII
S/S: easy bruising, nosebleeds, heavy menses, increased bleeding after surgery, dental work, or injury
Treatment: depends on type and severity
Desmopressin (DDAVP) —> increased vWF release (most cases)
vWF/Factor VIII concentrate for severe cases
antifibrinolytics (ex. TXA)
Hemophilia A & B
Definition:
X-linked bleeding disorders affecting the intrinsic pathway
Hemophilia A: factor VIII deficiency
Hemophilia B: factor IX deficiency
Testing:
increased aPTT (normal PT and platelets)
Factor VIII or IX assay —> differentiates A vs B
S/S:
prolonged bleeding, easy bruising
hemarthrosis —> joint pain and swelling
excessive bleeding after injury or surgery
Treatment:
factor VIII replacement —> Hemophilia A
factor IX replacement —> Hemophilia B
DDAVP —> mild Hemophilia A
antifibrinolytics (TXA) —> stabilize clots
avoid NSAIDs and trauma
Disseminated intravascular coagulation (DIC)
Definition: secondary process —> widespread activation of clotting —> microthrombi + factor consumption —> bleeding
Testing: increased PT/aPTT, increased D-dimer, decreased platelets, decreased fibrinogen, fragmented RBCs (schistocytes) by mechanical damage
S/S: bleeding (bruising, oozing), thrombosis, organ ischemia
Treatment:
treat underlying cause (sepsis, trauma, obstetric)
supportive: fresh frozen plasma, platelets, cryoprecipitate if bleeding
heparin of predominately thrombotic
Key point: causes both clotting and bleeding because microthrombi consume platelets and clotting; treat the underlying cause first
Immune Thrombocytopenic Purpura (ITP)
Definition: autoimmune platelet destruction —> isolated thrombocytopenia (< 100,000 platelets)
Testing: CBC = low platelets, normal WBC/RBC; peripheral smear normal morphology
S/S: petechiae, purpura, mucosal bleeding, nosebleeds, gum bleeding
Treatment:
corticosteroids (first line)
IVIG or Rho(D) immune globulin if severe
splenectomy for refractory cases
avoid NSAIDs/aspirin
Hemostatic Therapy
Purpose: prevent or control excessive bleeding caused by impaired clot formation or excessive clot breakdown
Mechanism: promote hemostasis through two major actions
increased clotting factor availability —> improved clot formation
decreased fibrinolysis —> stabilization of existing clots
Examples:
Desmopressin (DDAVP) —> increased release of vWF and factor VIII —> improves clot formation
Tranexamic acid (TXA) —> blocks plasminogen binding to fibrin —> prevents clot breakdown
Aminocaproic acid (Amicar) —> blocks plasminogen activation —> prevents clot breakdown
Major risks: thromboembolic complications in susceptible patients
Key point:
DDAVP promotes clot formation
antifibrinolytics prevent clot breakdown
Desmopressin (DDAVP)
Class: synthetic ADH analog —> hemostatic analog
MOA: stimulates V2 receptors —> increased release of vWF and Factor VIII —> increased clot formation
Route: IV, SC, intranasal (formulation dependent)
Use: selected patients with mild Hemophilia A or von Willebrand disease (primarily type 1)
Major ADR: hyponatremia, water intoxication, headache, flushing
Contraindications: hyponatremia, significant renal impairment, certain cardiac conditions
Nursing:
monitor: serum sodium, fluid balance, urine ouptut
fluid restriction: limit free water —> prevent water intoxication
assess: headache, confusion, weight gain —> possible hyponatremia
safety: monitor response to therapy; repeated doses may have decreased effect over time (tachyphylaxis)
Key point:
DDAVP increases vWF and factor VIII
antifibrinolytics prevent fibrin breakdown
Tranexamic acid (TXA)
MOA: blocks plasminogen binding to fibrin —> decreased fibrin breakdown
Route: PO, IV, topical (often off-label)
Uses: trauma, surgery, postpartum hemorrhage, heavy menses, epistaxis
Major ADR: seizures (high doses), hypotension (rapid IV), thrombotic complications
Nursing:
monitor: bleeding control and signs of DVT/PE
administration: give IV slowly —> rapid administration may cause hypotension
renal function: assess kidney function —> may require dose adjustment
safety: avoid with active intravascular clotting; assess thrombotic risk
Aminocaproic Acid (Amicar)
MOA: inhibits plasminogen activation —> decreased plasmin —> decreased fibrin breakdown
Route: PO/IV
Uses: surgical bleeding, excessive fibrinolysis, hemophilia-related bleeding
Major ADR: hypotension (rapid IV), myopathy, thrombotic complications
Nursing:
monitor: bleeding control and signs of DVT/PE
administration: give IV slowly —> rapid administration may cause hypotension
renal function: assess kidney function —> may require dose adjustment
safety: avoid with active intravascular clotting; assess thrombotic risk
Other conditions that impair coagulation
Liver disease:
Effect on coagulation: decreased clotting factors and decreased natural anticoagulants (ex. protein C/S, antithrombin)
Bleeding/Clotting risk: increased bleeding and thrombosis risk
Treatment: treat underlying disease process; blood products or vitamin K when indicated
Hypothermia & metabolic acidosis:
Effect on coagulation: decreased clotting factor activity and platelet function
Bleeding/Clotting risk: increased bleeding risk
Treatment: rewarming and correction of acidosis
Vitamin K:
Effect on coagulation: decreased functional factors II, VII, IX, X
Bleeding/Clotting risk: increased bleeding risk
Treatment: vitamin K (phytonadione)
Hypocalcemia:
Effect on coagulation: required cofactor (factor IV) for coagulation reactions
Bleeding/Clotting risk: increased bleeding risk (especially if severe)
Treatment: calcium replacement (when indicated)
Shock
Definition: inadequate tissue perfusion —> decreased oxygen delivery —> anaerobi metabolism —> increased lactic acid —> metabolic acidosis —> cell injury —> organ dysfunction
Goal of Compensation: maintain perfusion via neurohumoral activation (SNS, RAAS, ADH)
Failure of Compensation: progressive ischemia —> multi-organ failure —> death
Imbalance:
increased oxygen demand —> increased metabolic demand
decreased oxygen supply
insufficient oxygen supply
inadequate tissue perfusion
cellular hypoxia
Progression: decreased O2 delivery —> anaerobic metabolism —> increased lactic acid and metabolic acidosis —> cell injury —> organ dysfunction
Common pathophysiology of shock
Initiating mechanism
decreased circulating volume, decreased cardiac output, or decreased vascular tone —> tissue hypoperfusion
Cellular dysfunction
decreased O2 delivery —> anaerobic metabolism —> increased lactate & metabolic acidosis —> decreased ATP production
Vicious cycle
decreased ATP —> cellular injury —> inflammation & endothelial dysfunction —> worsening hypoperfusion —> organ dysfunction
Stages of shock
Initial: decreased CO and O2 delivery —> early anaerobic metabolism
Compensatory: SNS + RAAS + ADH activation —> increased HR, increased RR, vasoconstriction, decreased urine output
Progressive: compensatory failure —> hypotension —> organ hypoperfusion
Irreversible: multi-organ failure —> ischemia —> death
Signs of shock
Early signs:
MAP decreased 10 mmHg from baseline
effective compensation
increased O2 —> vital organs
increased heart rate
Compensatory signs (non-progressive):
MAP decreased 10-15 mmHg from baseline
increased renin-angiotensin-aldosterone (RAAS)/ADH
vasoconstriction
increased pulse pressure
increased HR
decreased pH
restless
apprehensive
Progressive (intermediate):
MAP decreased 20 mmHg from baseline
tissue/organ hypoxia
decreased urine (oliguria)
weak, rapid pulse
decreased pH
sensory/neurologic changes
Refractory signs (irreversible):
excessive cell/organ damage
multi-system organ failure
decreased pH
Vascular response
Trigger: baroreceptors in the carotid sinuses & aortic arch detect drop in BP
Mechanism: decreased stretch —> SNS activation …
arteriolar vasoconstriction —> increased SVR —> supports increased BP
venoconstriction —> increased venous return —> increased preload & CO
blood redistribution —> prioritizes heart and brain perfusion
Result: maintains BP and vital organ perfusion during early shock
Prolonged shock:
sustained vasoconstriction —> decreased skin, renal, GI perfusion
endothelial injury + systemic inflammation —> coagulation activation —> microthrombi and clotting consumption —> DIC
Chemoreceptor response
Trigger: peripheral chemoreceptors (carotid & aortic bodies) detect decreased O2, increased CO2, or decreased pH
Mechanism: stimulates medulla —> SNS activation
increased HR and contractility —> increased CO
vasoconstriction —> maintain BP and oxygen delivery
increased respiratory rate —> blow off CO2 —> correct acidosis
Timeline: rapid (seconds) —> maintains short-term oxygenation
Limitation: if hypoxia persists —> lactic acidosis —> chemoreceptor fatigue
Renal response
Trigger: decreased renal perfusion —> juxtaglomerular cells release renin (10-60 min)
Cascade:
renin —> angiotensin I —> angiotensin II —> potent vasoconstriction —> increased BP
angiotensin II —> stimulates aldosterone —> sodium and water retention —> increased intravascular volume
Early indicator: decreased urine output = renal hypoperfusion
Late effect: persistent ischemia —> acute tubular necrosis (ATN) —> renal failure
Adrenal response
SNS —> Adrenal medulla —> Epi/NE: increased HR, contractility, and vasoconstriction —> increased BP and CO —> rapid perfusion support
HPA Axis —> Adrenal cortex —> Cortisol: increased catecholamine sensitivity & glucose availability —> sustained vascular and metabolic support
Clinical significance:
short-term: maintains BP & tissue perfusion:
prolonged stress: hyperglycemia & immunosuppression —> increased complications
Cerebral response
Goal: maintain constant cerebral blood flow despite systemic hypotension
Mechanism: autoregulation dilates cerebral arterioles when MAP decreases or CO2 increases
Critical threshold:
CPP (60-100) = Map (70-100) - ICP (5-15)
ischemia occurs if CPP < 60 mmHg
Progression: prolonged hypotension —> loss of autoregulation —> cerebral hypoxia, edema, decreased LOC, coma
Hepatic response
Epinephrine: stimulates glycogenolysis —> glucose release for energy
Vasoconstriction: shunts flow to vital organs —> risk of hepatic ischemia
Metabolic Role: impaired lactate clearance & detoxification —> increased toxins, ammonia, lactic acidosis —> to multi-organ failure (MODS)
Pulmonary response
Acidosis —> tachypnea: compensatory hyperventilation (Kussmaul-type) to decrease CO2
Result: temporary pH correction and improved alveolar O2 exchange
Progression: endothelial injury —> increased capillary permeability —> pulmonary edema —> decreased gas exchange —> ARDS
Classification of shock
Obstructive:
compression/obstruction
cardiac tamponade
tension pneumothorax
Cardiogenic:
pump failure
blunt cardiac injury
dysrhythmia
myocardial infarcation
Hypovolemic:
reservoir depletion
hemorrhage
hypovolemia
Distributive:
vasodilation
anaphylaxis
sepsis
spinal cord injury (neurogenic shock)
Key point: all lead to inadequate tissue perfusion
Hypovolemic shock
Mechanism: decreased intravascular volume —> decreased venous return (preload) —> decreased CO —> decreased tissue perfusion
Compensatory: increased HR, vasoconstriction, fluid shift —> fail with severe loss
Types:
hemorrhagic: trauma, GI bleed, aneurysm rupture, post-surgical bleed
non-hemorrhagic: dehydration, burns, vomiting, diarrhea, diuresis, third-spacing (peritonitis, burns)
S/S:
- Early:
tachycardia, hypotension, narrow pulse pressure (decreased stroke volume)
cool, clammy, pale skin (peripheral vasoconstriction —> increased SVR)
oliguria < 0.5 mL/kg/hr (decreased renal perfusion)
anxiety, restlessness (decreased cerebral perfusion)
hemodynamics: decreased preload (CVP), decreased CO from decreased venous return, increased SVR compensatory response
- Advanced:
hypotension unresponsive to fluids; weak, thready pulses
hypothermia (impaired thermoregulation from poor perfusion)
confusion —> lethargy —> coma (cerebral hypoxia)
hemodynamics: persistently decreased CO despite fluid resuscitation, decreased mixed venous O2 saturation (increased extraction), narrow or collapsing pulse pressure
Diagnostics:
- Laboratory findings:
decreased Hgb/Hct: after fluid shift; may be normal early
increased lactate: marker of tissue hypoperfusion
increased BUN/Cr (> 20:1): prerenal azotemia from hypoperfusion
increased Na+/osmolarity: especially with dehydration
metabolic acidosis: from anaerobic metabolism (lactic acid)
coagulopathy: increased PT/INR, decreased platelets in hemorrhagic shock or with MTP
- Imaging & additional evaluation:
FAST(focused assessment with sonography in trauma): detect intra-abdominal bleeding
CT or angiography: localize internal hemorrhage
CXR/PXR: identify fractures or bleeding sources
continuous hemodynamic and urine output monitoring: assess response to resuscitation
Treatment:
Fluid resuscitation:
start with crystalloids (NS or LR) —> rapid infusion
if hemorrhagic —> activate massive transfusion protocol (1:1:1 PRBC: FFP: platelets)
Hemostatic measures:
identify and control bleeding source (surgical, mechanical, or interventional)
apply direct pressure or hemostatic dressings
consider early tranexamic acid (TXA) to stabilize clot formation
Monitor: mental status, MAP ≥ 65 mmHg, urine output, lactate
Vasopressors: norepinepherine —> only after adequate volume restoration
Correct underlying cause: control bleeding, treat dehydration, burns, etc.
Key point:
tachycardia, narrow pulse pressure, and cool, clammy skin may precede hypotension and can be a compensatory response
a normal blood pressure does not exclude significant hypovolemia
progressive loss of intravascular volume —> compensatory vasoconstriction (increased DVR) —> decreased venous return and CO —> tissue hypoperfusion (renal, cerebral, systemic)
Cardiogenic shock
Definition: pump failure leading to decreased CO, resulting in inadequate tissue perfusion
Patho: decreased cardiac contractility (pump failure) —> decreased cardiac output —> increased LV filling pressures —> pulmonary congestion & hypoxia —> decreased systemic perfusion (multi-organ hypoperfusion)
Cycle: decreased CO —> decreased coronary perfusion —> increased myocardial ischemia —> further decreased contractility. —> cycle repeats (vicious cycle)
Common causes:
myocardial infarction (MI) (most common)
cardiomyopathy (ex. dilated, hypertrophic)
arrhythmias (ex. VT, high-grade heart block)
valvular disease (ex. mitral regurgitation, aortic stenosis)
Hemodynamic findings:
decreased cardiac output (CO) and cardiac index (CI)
increased filling pressures: increased PCWP (≥ 18 mmHg) and increased CVP
increased systemic vascular resistance (SVR)(compensatory)
Clinical presentations:
chest pain (commonly from MI)
dyspnea, orthopnea, crackles/rales (pulmonary congestion)
cyanosis, cool, clammy skin (decreased perfusion)
decreased urine output (< 0.5 mL/kg/hr)
JVD + hepatic congestion (if right ventricular failure)
weak or thready pulses, hypotension, tachycardia
altered mental status, anxiety, restlessness (decreased cerebral perfusion)
Diagnostics/Findings:
EKG: ST elevation or arrythmia (ex. VT, AFib, HB)
Echocardiogram: decreased LVEF, wall motion abnormalities, decreased stroke volume
Labs: increased troponin, increased BNP, increased lactate (tissue hypoperfusion)
CXR: pulmonary congestion or edema; possible cardiomegaly
Treatment:
Inotropes: dobutamine or milrinone —> increased contractility and CO
Vasopressors: norephineprine —> maintain MAP ≥ 65 mmHg
Diuretics: furosemide —> decreased pulmonary congestion
Revascularization: PCI or CABG for MI-related shock
Mechanical support: IABP or LVAD for refractory cases
Avoid fluid overload: worsense pulmonary edema
Obstructive shock
Definition: mechanicla blockage to cardiac filling or output, leading to decreased CO and tissue perfusion
Patho: mechanical obstruction (to filling or output) —> decreased venous return (preload) —> decreased cardiac output (CO) —> decreased tissue perfusion (shock)
Common causes:
pulmonary embolism (increased RV afterload)
tension pneumothorax (mediastinal shift —> decreased venous return)
cardiac tamponade (increased pericardial pressure —> decreased filling)
aortic dissection (compromised major arterial flow)
Hemodynamics: decreased CO, decreased preload, increased RAP/CVP, increased SVR (compensatory)
Clinical presentations:
sudden, severe hypotension with tachycardia and weak, thready pulses (decreased preload and CO)
dyspnea, tachypnea, cyanosis (impaired oxygenation)
distended neck veins/JVD (increased right atrial pressure, venous congestion)
cool, clammy skin (SNS vasoconstriction
restlessness, anxiety, altered LOC (early cerebral hypoperfusion)
pulsus paradoxus (exaggerated > 10 mmHg drop in systolic BP during inspiration; notably in tamponade)
Specific presentations:
cardiac tamponade
muffled heart sounds
narrow pulse pressure
increased JVD, clear lungs
tension pneumothorax
absent breath sounds (affected side)
tracheal deviation
sudden hypoxia
pulmonary embolism
pleuritc chest pain
tachypnea, hypoxia
± hemoptysis
aortic dissection
sudden “tearing” chest or back pain
pulse deficits
differential BP between arms
Diagnostics:
EKG: right strain, electrical alternans
Echo: RV dilation, pericardial effusion
CTA: PE or aortic dissection
CXR: pneumothorax
Treatment:
PE: tPA or catheter thrombolysis —> heparin LMWH
Tension pneumothorax: immediate needle decompression —> chest tube
Tamponade: pericardiocentesis —> surgical window if recurrent
Dissection: urgent surgery + BP control (B-blocker)
Distributive shock
Definition: systemic vasodilation causing relative circulatory insufficiency and tissue hypoperfusion
Patho: widespread vasodilation (decreased SVR) —> blood pooling (capacitance) —> decreased venous return (preload) —> decreased cardiac output (CO)
Subtypes: septic, anaphylactic, neurogenic
Hemodynamics: increased CO (normal or high), decreased SVR, decreased preload
Clinical Presentation:
warm skin initially (vasodilation)
cool skin as hypoperfusion progresses
Key point: pathologic, widespread vasodilaltion causing decreased SVR, blood pooling, and decreased CO
Septic shock
Patho: infection —> cytokine storm (IL-1, IL-6, TNF-alpha) —> endothelial damage —> increased nitric oxide —> massive vasodilation
Clinical presentation:
- Hyperdynamic (warm) phenotype
normal increased CO, decreased SVR
warm, flushed skin; bounding pulses
widened pulse pressure (vasodilation)
- Hypodynamic (cold) phenotype
decreased CO (often), impaired tissue perfusion
cool, mottled skin; weak pulses
narrow pulse pressure may occur
Diagnostic findings:
- Laboratory
lactate (≥ 2 mmol/L) —> tissue hypoperfusion (≥ 4 mmol/L = higher risk)
WBC —> leukocytosis or leukopenia (late)
procalcitonin —> supports bacterial infection
blood cultures (positive) —> identify organism (often gram-negative)
CRP/ESR —> systemic inflammation
metabolic acidosis (decreased pH, HCO3-) —> tissue hypoxia
organ injury labs (increased BUN/Cr, increased LFTs, increased bilirubin, increased troponin)
- Imaging/Evaluation
CXR/CT/Ultrasound —> identify infection source (ex. pneumonia, abscess)
Echocardiography —> assess cardiac function if hypotension persists
Treatment:
antibiotics —> broad spectrum within 1 hour and then tailor to cultures
fluids —> 30 mL/kg crystalloid (NS/LR)
vasopressors —> norepinephrine (1st line), add vasopressin if needed
source control —> drain abscess; remove infected catheters or devices
monitoring (goals) —> MAP ≥ 65 mmHg; lactate clearance (≥ 10-20% decrease in 2-6 hours)
adjuncts —> hydrocortisone if refractory to pressors; O2 support; nutrition
Key point:
produces variable hemodynamic patterns
patients may present with a warm, hyperdynamic or cold, hypodynamic phenotype —> progression between these states is not inevitable
Dx: identify infection and assess severity (lactate, cultures, organ injury, imaging)
Tx: early antibiotics, fluids, vasopressors, source control, and goal directed monitoring
Anaphylactic shock
Patho:
allergen (food, drug, insect sting) —> IgE mediated mast cell-basophil degranulation —> release of histamine, tryptase, leukotrienes, prostaglandins —> vasodilation (decreased SVR), increased capillary permeability (decreased preload), bronchoconstriction, edema
Clinical presentation:
rapid onset (minutes) after exposure
skin: urticaria, flushing, pruritus, angioedema
respiratory: wheezing, stridor, dyspnea
cardiovascular: hypotension, tachycardia, syncope
GI: nausea, vomiting, cramping, diarrhea
hemodynamics: decreased SVR, decreased preload, decreased CO (may occur)
Diagnosis:
mostly clinical: rapid onset of typical symptoms (ex. airway, respiratory, cardiovascular, skin, or GI) after allergen exposure (ex. food, drug, insect sting)
Treatment:
Epinephrine (first-line): 0.3-0.5 mg IM in the mid-anteriolateral thigh; repeat q5-15 min
airway & O2: O2 and airway support (ex. impending airway edema)
fluids: rapid isotonic crystalloid (ex. 1-2 L)
adjuncts: H1 antihistamine (ex. diphenhydramine), H2 blocker (famotidine), and corticosteroid (methylprednisolone)
observation: ≥ 4-6h (longer if severe or biphasic risk)
Key point:
life-threatening allergic reaction with rapid onset
Epinephrine IM is the first-line, immediate treatment
treat airway, breathing, and circulation, and monitor for recurrence (biphasic reaction)
Neurogenic shock
Definition: distributive shock from loss of sympathetic tone, commonly after spinal cord injury (SCI)
Patho: loss of sympathetic tone (ex. SCI ≥ T6) —> unopposed vagal activity (increased parasympathetic) —> systemic vasodilation (decreased SVR) —> decreased venous return (decreased preload) —> decreased CO and BP with bradycardia (hallmark)
Causes:
spinal cord injury: cervical or upper thoracic (T1-T6)
head trauma: brainstem injury affecting autonomic control
spinal anesthesia: rare sympathetic blockade
CNS insult: tumors, lesions, or demyelinating disease
Clinical presentation:
- Early:
decreased BP with bradycardia (hallmark)
warm, dry, flushed skin below injury (loss of vasomotor tone)
flaccid paralysis, decreased reflexes, anhidrosis below lesion
normal or decreased JVD (no venous congestion)
hypothermia from vasodilation & impaired thermoregulation
- Progressive
dizziness, syncope, decreased LOC (decreased cerebral perfusion)
decreased urine output (renal hypoperfusion)
respiratory compromise if injury above C5 (decreased diaphragmatic function)
decreased sweating below lesion (impaired temperature control)
Diagnostic findings:
- Clinical assessment:
vital signs —> hypotension + bradycardia (± hypothermia)
neurologic exam —> deficits consistent with high spinal cord injury (≥ T6)
history/mechanism —> trauma or other spinal cord injury (ex. spinal anesthesia
- Imaging/Evaluation:
MRI/CT spine: confirm level and extent of spinal cord injury
Other studies: rule out other causes of shock (ex. hemorrhagic, septic, cardiogenic)
Treatment:
IV fluids: cautious volume replacement (ex. 500-1000 mL crystalloid) to optimize preload)
maintain BP: target MAP ≥ 85 mmHg to ensure spinal cord perfusion; avoid fluid overload
vasopressors: norephinephrine (preferred) or phenylephrine ro restore vascular tone
atropine: for symptomatic bradycardia
spinal stabilization/decompression: surgical or mechanical management as indicated
respiratory support: if high cervical injury (ex. ≥ C5), provide ventialotry support
prevent secondary injury: maintain oxygenation, normothermia, and adequate perfusion
Key point: NOT spinal shock
results from loss of sympathetic tone with vasodilation and bradycardia, whereas spinal shock is a transient loss of all neurologic function after SCI
MODS (multiple organ dysfunction syndrome)
Patho: persistent hypoperfusion + systemic inflammation —> dysfunction of ≥ 2 organ systems
Key clinical findings:
oliguria (decreased urine output)
altered LOC
respiratory failure
hepatic dysfunction (increased liver enzymes)
ARDS (acute respiratory distress syndrome)
Patho: inflammatory alveolar-capillary injury —> pulmonary edema + impaired gas exchange
Key clinical findings:
severe hypoxemia (decreased spO2)
dyspnea/increased work of breathing
bilateral pulmonary opacities (ex. on CXR)
Virchow’s Tirad
Venous stasis: slowed blood flow —> immobility, bed rest, prolonged travel
Endothelial injury: vessel wall damage —> surgery, trauma, catheters
Hypercoagulability: increased tendency to clot —> inherited thrombophilia, cancer, pregnancy
Key point: explains the major mechanisms contributing to venous thrombosis
Venous thrombosis (& Virchow’s triad)
Definition: abnormal thrombus formation —> partial or complete obstruction of blood flow
Thrombus formation:
platelets + fibrin + RBCs —> clot formation
clot obstructs circulation —> impaired blood flow
Virchow’s triad:
Venous stasis: slowed blood flow —> immobility, bed rest, prolonged travel
Endothelial injury: vessel wall damage —> surgery, trauma, catheters
Hypercoagulability: increased tendency to clot —> inherited thrombophilia, cancer, pregnancy
Key point: explains the major mechanisms contributing to venous thrombosis
Thrombus vs. Embolus
Thrombus:
blood clot that forms and remains within a blood vessel
may partially or completely obstruct blood flow
Embolus:
clot or other material that travels through circulation
lodges in another vessel —> impaired perfusion
Venous thromboembolism (VTE):
Deep vein thrombosis (DVT): thrombus forms in a deep vein, usually in the leg
Pulmonary embolism (PE): embolus travels to and obstructs a pulmonary artery
Key point: a DVT can dislodge —> travel to the lungs —> cause a potentially life-threatening arterial blockage in the pulmonary arteries called a PE
DVT (deep vein thrombosis)
Definition: thrombus formation in a deep vein, most commonly in the lower extremities
Patho:
Virchow’s triad —> promotes venous thrombus formation
thrombus obstructs venous flow —> increased venous pressure
impaired venous return —> swelling, pain, and inflammation
thrombus may dislodge —> pulmonary embolism
Complications:
PE: embolism to pulmonary circulation
post-thrombotic syndrome: venous valve damage —> chronic edema, pain, skin changes or ulcers
Virchow’s triad:
venous stasis: slowed blood flow (ex. immobility, bed rest)
endothelial injury: vessel wall damage (ex. surgery, trauma)
hypercoagulability: tendency to clot (ex. cancer, pregnancy)
Risk factors:
immobility: bed rest, hospitalization, prolonged travel
surgery or trauma: especially orthopedic procedures
hypercoagulable conditions: cancer, pregnancy, estrogen therapy, inherited thrombophilia
other risks: previous DVT/PE, obesity
Clinical manifestations:
unilateral pain swelling
pain or tenderness, commonly in the calf
warmth, erythema, or discoloration
may be asymptomatic
Nursing priorities:
assess and compare both extremities
do not massage the affected leg
notify provider —> anticipate diagnostic ultrasound
Clinical Probability:
Wells score: estimates likelihood of DVT based on symptoms and risk factors
guides laboratory testing and imaging
Laboratory testing:
D-dimer: measures fibrin degradation products
negative D-dimer: helps exclude DVT in appropriately selected low-risk patients
elevated D-dimer: nonspecific —. does not confirm DVT
Diagnostic imaging:
Venous duplex ultrasound: first-line diagnostic test
thrombus —> vein does not compress normally
computed tomography (CT) or magnetic resonance (MR) venography: selected cases when ultrasound is inconclusive or pelvic DVT is suspected
Key point:
impairs venous return and may cause life-threatening PE
new unilateral swelling + pain + warmth —> suspect DVT
D-dimer helps rule out DVT in selected patients; duplex ultrasound confirms the diagnosis
DVT management
Pharmacologic management:
anticoagulants: first line for most confirmed DVTs —> prevent clot extension + new clot formation
DOACs: apixaban, rivaroxaban —> preferred for many eligible patients
UFH/LMWH: alternatives —> based on clinical circumstances
warfarin: used in selected patients —> requires INR monitoring
duration: ≥ 3 months —> longer if recurrent DVT or high bleeding risk
Nonpharmcologic management:
early ambulation: once anticoagulated + clinically stable
limb care: avoid massaging the affected extremity
limb-threatening DVT: urgent vascular evaluation —> possible catheter-directed treatment for clot removal
Monitoring & safety:
bleeding: brusing, hematuria, GI bleeding, severe headache
UFH: monitor aPTT or anti-Xa (as ordered)
HIT: monitor platelet counts (when indicated)
PE warning signs: sudden dyspnea, chest pain, tachycardia, immediate evaluation
Prevention Strategies:
- Enhance mobility:
early ambulation: get patients moving as soon as it is safe
regular mobility: leg exercises (ex. ankle pumps) and frequent walks
- Use prophylaxis:
mechanical: sequential compression devices (SCDs) or compression stockings (when indicated)
pharmacologic: anticoagulants (ex. low dose UFH or LMWH) for eligible at-risk patients
Key point:
anticoagulants prevent blood clot progression; bleeding and signs of PE are major nursing priorities
early mobility, leg exercises, and apporpriate mechanical or pharmacological prophylaxis prevent the first DVT
Pulmonary Embolism (PE)
Definition: embolus, usually from a DVT, obstructs pulmonary arterial blood flow
can also arise from fat, air, amniotic fluid
Effects on Oxygenation:
obstructed pulmonary blood flow —> ventilation-perfusion mismatch (V/Q mismatch)
impaired gas exchange —> possible hypoxemia
Patho:
pulmonary artery obstruction —> increased pulmonary vascular resistance
increased resistance —> increased right ventricular (RV) afterload
RV dilation and dysfunction —> decreased left ventricular filling
decreased cardiac output —> hypotension and obstructive shock
Complications:
acute RV failure
obstructive shock and cardiac arrest
chronic thromboembolic pulmonary hypertension (CTEPH) —> persistent dyspnea
Common manifestations:
sudden dyspnea and tachycardia
pleuritic chest pain —> worsens with inspiration
tachycardia and possible hypoxemia
possible hemoptysis, anxiety, or syncope
High-risk findings:
hypotension —> decreased cardiac output
altered mental status —> impaired cerebral perfusion
cool skin, poor perfusion, or syncope
severe PE —> obstructive shock or cardiac arrest
Nursing priorities:
assess airway, breathing, circulation (ABCs)
monitor SpO2, BP, HR, and mental status
recognize hemodynamic deterioration —> activate emergency response
Clinical probability:
Wells score: estimates likelihood of PE
clinical probability and hemodynamic stability guide testing
Laboratory testing:
D-dimer: helps exclude PE in appropriately selected low-intermediate-risk patients
elevated D-dimer: nonspecific —> does not confirm PE
troponin/natriuretic peptides: may indicate RV strain and assist risk assessment
Diagnostic imaging:
CT pulmonary angiography (CTPA): primary confirmatory imaging test for most eligible patients
Ventilation/perfusion (V/Q) scan: alternative when CTPA is unsuitable
Echocardiography: evaluates RV dysfunction, especially in unstable patients
Additional assessment:
EKG: may show sinus tachycardia
ABGs: may show hypoxemia or respiratory alkalosis
neither EKG nor ABGs alone can confirm or exclude PE
Key point:
pulmonary obstruction —> RV strain —> decreased cardiac output —> potentially fatal obstructive shock
sudden dyspnea + chest pain + hypotension —> suspect life-threatening PE
clinical probability guides testing; CTPA is the primary confirmatory test for most eligible patients
PE management
Anticoagulation:
anticoagulation —> first-line for most patients; prevents recurrence
oral therapy —> DOACs preferred when eligible
injectible therapy —> LMWH over UFH when parenteral treatment is needed
warfarin —> preferred in thrombotic antiphospholipid syndrome
Thrombolytic therapy:
alteplase —> promotes clot breakdown
consider for high-risk PE with hemodynamic instability and acceptable bleeding risk
avoid routine thrombolysis in stable PE
Monitoring & safety:
watch for major bleeding (GI or intracranial)
review contraindications, renal function, and drug interactions
monitor BP, oxygenation, mental status, and response
initial treatment —> 3-6 months: reassess need for extension
Oxygenation & supportive care:
assess ABGs and monitor respiratory status —> maintain oxygenation
give supplemental oxygen for hypoxemia (SpO2 < 90%)
manage hypotension and impaired perfusion —> vasopressors (if needed)
escalate for worsening respiratory distress
Antithrombotic adjunct: inferior vena cava (IVC) filter
consider when VTE is present and anticoagulation is contraindicated
traps emboli to prevent new PE
does not dissolve existing clot
remove when appropriate —> typically within 3 months (or sooner if possible)
Advanced interventions (for select patients:
catheter-directed therapy (CDT): catheter delivery of a thrombolytic (ex. altepase) ± mechanical clot removal into pulmonary arteries
surgical embolectomy: urgent clot removal when indicated
Prevention strategies:
early mobility
ambulate early and regularly
reduce venous stasisand VTE risk, including PE
mechanical prophylaxis
use sequential compression devices (SCDs) when appropriate
promote venous return and reduce stasis
pharmacologic prophylaxis
give risk-based anticoagulation during hospitalization (ex. LMWH or UFH)
prevent VTE (DVT and PE) in at-risk patients
Key points:
anticoagulants —> prevent recurrent VTE; do not actually dissolve existing clot
thrombolytics —> actively dissolve clots in selected unstable patients
use early mobility, SCDs, and risk based anticoagulation to prevent a first PE (primary prevention)
Ischemic stroke
Definition: cerebral artery obstruction —> decreased cerebral blood flow —> neuronal injury and infarction
Etiology:
atherosclerotic (large-artery): plaque formation or rupture —> thrombosis or embolization
cardioembolic: clot forms in the heart )ex. atrial fibrillation) —> travels to cerebral circulation
small vessel (lacunar): occlusion of small penetrating cerebral arteries
often associated with chronic hypertension or diabetes
Underlying mechanism:
arterial obstruction —> decreased oxygen and glucose delivery
prolonged ischemia —> irreversible brain injury
Patho:
- Cerebral ischemia:
arterial occlusion —> decreased oxygen and glucose
decreased adenosine triphosphate (ATP) production —> failure of cellular ion pumps
cellular sodium and water accumulation —> cytotoxic edema
prolonged ischemia —> neuronal injury and infarction
- Infarct core vs. penumbra:
infarct core: irreversibly injured brain tissue
ischemic penumbra: hypoperfused tissue that may still be salvageable
without reperfusion —> penumbra may progress to infarction
- Treatment implication:
rapid reperfusion may restore blood flow and preserve threatened tissue
delayed treatment —> greater risk of permanent neurological deficits
Risk factors:
- Modifiable:
hypertension —> major risk factor
diabetes mellitus, dyslipidemia
smoking, obesity, physical inactivity
atrial fibrillation —> increased risk of cardioembolic stroke
- Nonmodifiable
increasing age
family history
prior transient ischemic attack (TIA) or stroke
sex-related differences in risk and outcomes
Clinical manifestations:
sudden unilateral weakness or numbness
facial droop, arm weakness
aphasia: difficulty speaking or understanding language
visual loss, dizziness, ataxia, or impaired balance
Stroke recognition: BE - FAST
Balance: difficulty
Eyes: sudden vision loss (usually one eye)
Facial: facial droop
Arm: arm weakness
Speech: speech difficulty
Time: call 911 immediately
Diagnostics:
immediate assessment
identify last-known-well time
assess ABCs, vital signs, and blood glucose
use NIHSS to quantify neurologic deficits and monitor changes
brain imaging
non-contrast CT of brain ≤ 20 minutes from arrival(urgent; excludes intracranial hemorrhage)
MRI: ≤ 60 minutes from arrival (more sensitive for early ischemic stroke)
vascular imaging
CT angiography (CTA): ≤ 30 minutes from arrival (detects large-vessel occlusion)
CT/MR perfusion: ≤ 60 minutes from arrival (helps identify potentially salvageable tissue in selected patients)
additional evaluation:
EKG: obtain early (detects atrial fibrillation or arrhythmias)
Ehocardiography: within 24hrs (evaluates possible cardiac embolic sources)
Labs: glucose, CBC, and coagulation studies: PT, INR, aPTT (± fibrinogen and platelet count)
Key point:
ischemic strokes have different causes, which influence acute treatment and secondary prevention
time is brain —> early reperfusion may save the ischemic penumbra
sudden focal neurological deficits —> active stroke response immediately
last known-well time + urgent brain imaging guide reperfusion eligibility
Ischemic stroke management
Pharmacologic:
initial assessment
CT or MRI: no intracranial hemorrhage
NIHSS: assess baseline stroke severity and neurological deficits
review anticoagulant use
check blood glucose and bleeding risk
ensure BP < 185/110 mmHg
IV thrombolytics
alteplase or tenecteplase —> fibrinolytics
treat eligible disabling stroke ≤ 4.5 hours (last known well time)
selected extended/unknown-onset —> imaging based eligibility
Post-thrombolysis management:
BP < 180/105 mmHg for 24 hrs
monitor for intracranial hemorrhage (ICH)
frequent neurologic and BP checks (first 24 hrs)
hold anticoagulants/antiplatelets for 24 hrs until follow up CT/MRI
Start secondary prevention
aspirin (ACA): start early after CT excludes bleeding (generally within 48 hrs); if thrombolytic given, wait 24 hrs and repeat CT/MRI first
anticoagulation: selected cardiembolic indications
statins: reduce future vascular risk
Nonpharmacologic:
mechanical thrombectomy (EVT)
endovascular removal of a clot from an occluded artery
for selected large-vessel occlusions
can be performed up to 24 hours after last known well-time (in selected patients)
early rehabilitation (when medically stable):
begin multidisciplinary rehabilitation assessment early once clinically stable
include physical, occupational, and speech-language therapy as directed
supportive care:
airway & oxygenation: maintain adequate oxygenatin (SpO2 ≥ 94%); treat hypoxia
blood pressure: avoid hypotension; follow reperfusion-specific BP targets (ex. after thrombolysis or thrombectomy)
temperature: treat fever (≥ 100.4 °F) and investigate the cause
glucose: correct hypoglycemia; manage persistent hyperglycemia (ex. 140-180 mg/dL) while avoiding overly intesive control
hydration: maintain euvolemia (adequate fluid volume); avoid dehydration
aspiration prevention: perform a swallow screen before oral intake
Primary prevention:
control medical risks:
hypertension —> treat: BP goal < 130/80 mmHg for most treated adults
diabetes: optimize glucose; manage weight
high cholesterol: statin when indicated by cardiovascular risk
atrial fibrillation: assess stroke risk; anticoagulate when indicated
healthy daily habits:
mediterranean-style diet; limit sodium
exercise ≥ 150 min/week moderate intensity; reduce prolonged sitting
stop smoking: avoid tobacco
maintain healthy weight and sleep
screen & individualize:
regular BP, glucose, lipid, and AF/risk assessment
address barriers to preventative care
aspirin in NOT routinely recommended solely to prevent a first stroke
Key point:
EVT restores blood flow in selected large-vessel occlusions, and supportive care plus early rehabilitation reduce secondary complications
start aspirin early once imaging excludes intracranial hemorrhgae; after thrombolysis, withhold for 24h and obtain follow-up CT/MRI
restore blood flow (reperfusion) when indicated and provide supportive care to prevent secondary brain injury
prevent a FIRST stroke: control BP and other vascular risks + sustain healthy habits
Ischemic stroke: cerebral edema & increased ICP
Development of cerebral edema:
ischemia —> cellular injury —> cytotoxic edema
later blood-brain barrier disruption —> vasogenic edema
severe swelling —> increased intracranial pressure (ICP)
Effects on cerebral perfusion:
increased ICP —> decreased cerebral perfusion
severe edema —> possible brain herniation
large cerebellar infarcts —> possible hydrocephalus and brainstem compression
Warning signs:
declining level of consciousness (LOC)
new or worsening neurological deficits
headache, vomiting, pupillary changes
Cushing’s triad —> late sign of increased ICP (hypertension, bradycardia, irregular respirations)
Management of cerebral edema:
urgent neurological reassessment and brain imaging
general measures: head of bed 30°, maintain oxygenation (SpO2 ≥ 94%), euvolemia, and normothermia
osmotherapy: hypertonic saline (ex. 3% NaCl) or mannitol to reduce ICP
decompressive surgery: for selected patients with life-threatening swelling
Key point:
sudden neurological deterioration may indicate cerebral edema or hemorrhage —> immediate escalation
Brain anatomy
Brain overview:
Cerebrum:
cognition, memory
voluntary motor/sensory integration
Cerebellum:
coordinates tone & balance via feeback loops
lesion —> ataxia
Brainstem
autonomic control (HR/BP/respiration)
reticular activation
Perfusion dependent:
high O2 and glucose need
rapid dysfunction with ischemia
Protective structures:
Scalp & skull: outer mechanical protection
Meninges: three layers (dura mater, araachnoid matter, pia matter) provide mechanical and barrier protection
CSF: buoyancy, waste clearance, and ICP stability (via the choroid plexus)
BBB: tight junctions between astrocytes; limits entry of toxins and pathogens
Disruption: plasma leak —> vasogenic edema —> increased ICP
Cerebral blood supply & CSF circulation
Main pathways to the brain:
anterior circulation (ICAs): right and left internal carotid arteries
posterior circulation (vertebrals —> basilar): right and left vertebral arteries join to fomr the basilar artery
Circle of Willis (collateral flow)
Blood supply: 2 internal carotid arteries (anterior) and 2 vertebral arteries (join to form the basilar artery; posterior) supply the brain and connect via the Circle of Willis
CSF flow (simplified):
produced by the choroid plexus (in ventricles)
ventricles (lateral —> third —> fourth)
subarachnoid space (around brain & spinal cord)
reabsorbed by arachnoid granulations (into venous sinuses)
CSF: produced by the choroid plexus in the ventricles, circulates through the ventricles to the subarachnoid space, and is reabsorbed by arachnoid granulation into venous sinuses
Cerebral blood flow & neurovascular regulation
Cerebral blood flow (CBF):
normal CBF: 50-60 mL/100g/min
neurons require a continuous supply of oxygen and glucose (aerobic metabolism)
Neurovascular unit: neurons, astrocytes, and endothelium work together (neurovascular unit) to match local blood flow to brain activity (increased activity —> increased CBF)
Autoregulation:
adjusts cerebral blood vessel diamter to keep CBF relatively constant despite changes in MAP (60-150 mHg)
may be impaired after brain injury (ex. TBI), making CBF more dependent on MAP
CO2 regulation:
increased CO2 (hypercapnia): vasodilation —> increased CBF and increased ICP
decreased CO2 (hypocapnia): vasoconstriction —> decreased CBF and increased risk of ischemia
Key point: CBF is regulated by the neurovascular unit, autoregulation, and CO2 levels; after TBI, autoregulation may be impaired, and abnormal CO2 levels can compromise cerebral perfusion and worsen secondary brain injury
Intracranial pressure (ICP) & Monro-Kellie Principle
Monro-Kellie Principle: the skull is a fixed volume containing: brain tissue + blood + CSF
Intracranial volume: small changes in one component must be balanced by changes in the others
Brain: 80%
CSF: 10%
Blood: 10%
ICP values:
normal: 5-15 mmHg
> 20 mmHg: concerning (increased risk of brain injury)
> 40 mmHg: high risk of herniation
Compensation sequence (increased volume):
increased CSF displacement (to spinal space)
decreased venous blood volume (venous outflow)
compensatory reserve exhausted
increased ICP and risk of herniation
Key point: the intracranial space is fixed, so an increase in the volume of brain tissue, blood, or CSF raises ICP
Cerebral perfusion pressure (CPP)
CPP = MAP - ICP
normal CCP (non-TBI): approximately 60-100 mmHg
severe TBI target: 60-70 mmHg; individualized
ICP > 22 mmHg: treat sustained elevations
Avoid hypotension and hypoxemia:
prevent secondary brain injury
Avoid aggressively raising CPP > 70 mmHg:
with fluids/vasopressors due to respiratory complications
Impaired autoregulation:
CBF becomes more pressure dependent
CPP targets may require individualization
Key point: in severe TBI, maintain adequate CPP while controlling ICP to preserve cerebral blood flow and prevent secondary brain injury
Cerebral edema
Vasogenic edema:
disruption of the blood brain barrier (BBB)
fluid leaks into the extracellular space
caused by trauma and inflammation
Cytotoxic edema:
cellular energy failure disrupts sodium-potassium pumps
Na+ and H2O accumulate inside brain cells
associated with hypoxia and ischemia
Key point: both types cause brain swelling —> increased ICP —> decreased cerebral perfusion —> secondary brain injury
Pathophysiology of increased ICP
Causes: trauma, hemorrhage, edema, tumor, infection, hydrocephalus
Compensation fails: increased intracranial volume —> increased ICP
Vicious cycle: increased ICP —> decreased CPP —> ischemia —> edema —> increased ICP
Consequences: herniation, coma, death
Signs of ICP
Early signs:
decreased LOC: restlessness, confusion, agitation
pupils: sluggish or unequal (anisocoria)
headache, nausea, projectile vomiting
Late sings:
fixed, dilated pupils
Cushing’s triad
increased BP (widened pulse pressure)
decreased HR
irregular respirations
posturing
decorticate (flexor)
decerebrate (extensor)
coma — brain death
Brain herniations
Definition: displacement of brain tissue across rigid barriers due to increased ICP
Key assessment clues:
decreased level of consciousness
pupillary changes (size or reactivity)
worsening neurologic signs (ex. new weakness, abnormal posturing)
Uncal (lateral transtentorial):
medial temporal lobe (uncus) shift inward and downward through the tentorial notch
hallmark: ipsilateral dilated nonreactive pupil (CN III)
may progress to brainstem compression
Central (downward transtentorial):
downward displacement of the diencephalon and midbrain through the tentorial notch
Hallmark: progressive bilateral pupillary changes (sluggish —> nonreactive, potentially dilated), decreased LOC, abnormal posturing, and respiratory changes
Key point:
LIFE-THREATENING EMERGENCY
brainstem compression can lead to respiratory and cardiovascular collapse
Assessment of brain injuries
Glasgow coma scale:
assesses eye, verbal, motor, responses
total score ranges 3-15
severity:
Mild: GCS 13-15 —> minor injury
Moderate: GCS 9-12 —> moderate injury
Severe: GCS ≤ 8 —> coma, needs airway protection
Mnemonic:
8 or less = intubate — GCS of 8 or less —> cannot protect airway
Pupillary reflex: checks brainstem function —> unequal or nonreactive pupils may indicate increased ICP or herniation
Mechanisms of TBI
Primary injury: immediate mechanical damage at the time of trauma
direct impact (ex. coup/contrecoup)
penetrating injury
acceleration-deceleration and rotational/shearing forces (ex. diffuse axonal injury)
immediate neuronal and glial injury
Secondary injury: evolving cellular and physiologic damage that develops over minutes to days
hypoxia
ischemia (reduced cerebral perfusion)
increased intracranial pressure (increased ICP)
inflammation
excitotoxicity (excess glutamate)
Key point: primary injury occurs at impact; secondary injury evolves afterward and is the major target of treatment

Types of traumatic brain injury (TBI)
Concussion:
presentation: transient loss of consciousness (LOC) or confusion
mechanism: metabolic (functional) injury; no structural damage
Contusion:
definition: focal cortical bruise
risk: seizure focus
Axonal shearing:
definition: diffuse axonal injury (DAI)
result: widespread axonal damage —> coma without gross bleed
Epidural hematoma:
source: arterial bleed (middle meningeal artery)
course: lucid interval —> rapid decline
Subdural hematoma:
source: venous bleed (bridging veins)
course: gradual onset; increased risk in elderly or anticoagulated patients
Subarachnoid hemorrhage (SAH):
cause: aneurysm rupture
presentation: sudden, severe (“thunderclap”) headache; nuchal rigidity
Key point: TBIs differ by mechanism, bleeding source, and clinical pattern — use these key features to recognize the type and guide timely, appropriate care
Skull fractures in neurotrauma
Definition: a break in one or more skull bones from blunt or penetrating head trauma; may be associated with intracranial injury
Common types:
linear: simple fracture line —> often stable; assess for underlying brain injury
depressed: bone pushed inward —> possible brain injury; may require surgical evaluation
basilar: fracture at skull base (anterior, middle, or posterior fossa) —> higher risk for CSF leak and infection
open (compound): break in skin or sinuses —> communication with external environment; increased risk for infection
Basilar skull fracture: Red flags:
periorbital ecchymosis —> “raccoon eyes”
mastoid ecchymosis —> battle sign
hemotympanum
clear rhinorrhea/otorrhea —> possible CSF leak
Nursing priorities:
report suspected basilar skull fracture (with aforementioned findings)
avoid blind nasal intubation (ex. NG tube, nasotracheal suctioning)
monitor for intracranial injury and infection (ex. meningitis)
Key point: if a basilar skull fracture is suspected, do NOT insert anything into the nose (ex. NG tube) and notify the provider immediately
Skull fractures: diagnostics & monitoring
CT head: first-line for acute blled or fracture
MRI: sensitive for DAI, posterior fossa lesions
EVD (external ventricular drain): measures/monitors ICP + drains CSF to relieve pressure
- avoid lumbar puncture if increased ICP (risk of herniation)
- trend neuro exams and pupil reactivity
Subarachnoid hemorrhage (SAH) management
Etiologies: aneurysmal (ruptured aneurysm) or traumatic (head injury)
Goals: secure aneurysm, prevent rebleeding, and maintain cerebral perfusion
Before treatment: monitor BP; avoid severe hypertension, hypotension, and large fluctuations
Nimodipine: start early; maintain euvolemia
Complications: delayed cerebral ischemia (days 4-14), hydrocephalus, and hyponatremia
Seizures: antiseizure prophylaxis only for selected high-risk patients; treat new-onset seizures promptly
Key point: prevent rebleeding and complications by controlling BP (individualized), giving nimodipine early, and monitoring for delayed cerebral ischemia (days 4-14)